CA2736621A1 - Amplification and detection reagents for hiv-1 - Google Patents
Amplification and detection reagents for hiv-1 Download PDFInfo
- Publication number
- CA2736621A1 CA2736621A1 CA2736621A CA2736621A CA2736621A1 CA 2736621 A1 CA2736621 A1 CA 2736621A1 CA 2736621 A CA2736621 A CA 2736621A CA 2736621 A CA2736621 A CA 2736621A CA 2736621 A1 CA2736621 A1 CA 2736621A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- sequence
- oligo
- hiv
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 25
- 238000003199 nucleic acid amplification method Methods 0.000 title claims description 81
- 230000003321 amplification Effects 0.000 title claims description 80
- 238000001514 detection method Methods 0.000 title claims description 27
- 239000000523 sample Substances 0.000 claims abstract description 133
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 82
- 238000012360 testing method Methods 0.000 claims abstract description 39
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 43
- 239000011541 reaction mixture Substances 0.000 claims description 27
- 239000013615 primer Substances 0.000 description 191
- 208000031886 HIV Infections Diseases 0.000 description 76
- 241000725303 Human immunodeficiency virus Species 0.000 description 41
- 239000000047 product Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 30
- 229920002477 rna polymer Polymers 0.000 description 30
- 150000007523 nucleic acids Chemical group 0.000 description 22
- 239000012634 fragment Substances 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 18
- 102100034343 Integrase Human genes 0.000 description 17
- 108010061833 Integrases Proteins 0.000 description 17
- 208000030507 AIDS Diseases 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 241000560067 HIV-1 group M Species 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 229930010555 Inosine Chemical group 0.000 description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 5
- 229960005542 ethidium bromide Drugs 0.000 description 5
- 229960003786 inosine Drugs 0.000 description 5
- 238000013081 phylogenetic analysis Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- -1 IDS Species 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011392 neighbor-joining method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- HCGYMSSYSAKGPK-UHFFFAOYSA-N 2-nitro-1h-indole Chemical group C1=CC=C2NC([N+](=O)[O-])=CC2=C1 HCGYMSSYSAKGPK-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101100378010 Bacillus subtilis (strain 168) accC1 gene Proteins 0.000 description 1
- 101100322122 Bacillus subtilis (strain 168) accC2 gene Proteins 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000556773 HIV-1 group N Species 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 101150070497 accC gene Proteins 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/945,943 US6852491B2 (en) | 2001-09-04 | 2001-09-04 | Amplification and detection reagents for HIV-1 |
| US09/945,943 | 2001-09-04 | ||
| CA2459354A CA2459354C (en) | 2001-09-04 | 2002-07-12 | Amplification and detection reagents for hiv-1 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2459354A Division CA2459354C (en) | 2001-09-04 | 2002-07-12 | Amplification and detection reagents for hiv-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2736621A1 true CA2736621A1 (en) | 2003-03-13 |
Family
ID=25483738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2736621A Abandoned CA2736621A1 (en) | 2001-09-04 | 2002-07-12 | Amplification and detection reagents for hiv-1 |
| CA2459354A Expired - Fee Related CA2459354C (en) | 2001-09-04 | 2002-07-12 | Amplification and detection reagents for hiv-1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2459354A Expired - Fee Related CA2459354C (en) | 2001-09-04 | 2002-07-12 | Amplification and detection reagents for hiv-1 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6852491B2 (OSRAM) |
| EP (3) | EP2385144A1 (OSRAM) |
| JP (3) | JP4413610B2 (OSRAM) |
| CA (2) | CA2736621A1 (OSRAM) |
| ES (1) | ES2458556T3 (OSRAM) |
| WO (1) | WO2003020878A2 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3219400A (en) * | 1999-02-03 | 2000-08-25 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and reagents for molecular detection of hiv-1 groups m, n and |
| WO2005067646A2 (en) * | 2004-01-07 | 2005-07-28 | Hitachi Chemical Research Center, Inc. | Primers and probes for the detection of hiv |
| EP1602736A1 (en) | 2004-06-04 | 2005-12-07 | Bio-Rad Pasteur | HIV type and subtype detection |
| KR101450497B1 (ko) * | 2004-09-14 | 2014-10-13 | 아고스 쎄라퓨틱스, 인코포레이티드 | 병원체의 균주 독립성 증폭 및 그에 대한 백신 |
| AU2011253599B2 (en) * | 2004-09-30 | 2013-12-12 | Gen-Probe Incorporated | Assay for detecting and quantifying HIV-1 |
| EP2975139B1 (en) | 2004-09-30 | 2019-11-06 | Gen-Probe Incorporated | Assay for detecting and quantifying hiv-1 |
| AU2006323930B2 (en) * | 2005-12-07 | 2012-06-21 | Janssen Sciences Ireland Uc | Methods, plasmid vectors and primers for assessing HIV viral fitness |
| US20090061413A1 (en) * | 2006-02-27 | 2009-03-05 | Salinas Frank G | Isothermal screening of hiv-1 related nucleic acids |
| EP2126137B1 (en) * | 2007-01-23 | 2017-06-07 | Janssen Pharmaceutica NV | Method for designing a drug regime for hiv-infected patients |
| US8221981B2 (en) * | 2007-07-30 | 2012-07-17 | Argos Therapeutics, Inc. | Primers and probes for the amplification and detection of HIV Gag, Rev and Nef polynucleotides |
| JP2009077712A (ja) * | 2007-09-11 | 2009-04-16 | F Hoffmann La Roche Ag | Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験 |
| WO2010013232A1 (en) * | 2008-07-29 | 2010-02-04 | Applied Materials Israel Ltd. | Mapping variations of a surface |
| WO2010135917A1 (zh) * | 2009-05-26 | 2010-12-02 | 厦门大学 | 一种检测核酸序列变异的方法 |
| EP2561104B1 (en) * | 2010-04-23 | 2015-11-04 | Genomic Vision | Detection of hsv dna rearrangements |
| EP2729583B1 (en) | 2011-07-05 | 2019-05-22 | The Govt. Of The U.S.A. As Represented By The Secretary Of The Department Of Health & Human Services | Hiv-1 genotyping assay for global surveillance of hiv-1 drug resistance |
| EP2809784A4 (en) * | 2012-01-31 | 2015-07-15 | Advanced Liquid Logic Inc | AMPLIFICATION SPREADERS AND PROBES FOR DETECTING HIV-1 |
| KR101912401B1 (ko) | 2012-02-03 | 2018-10-26 | 캘리포니아 인스티튜트 오브 테크놀로지 | 다중화된 생화학적 분석에서의 시그널 인코딩 및 디코딩 |
| EP2880184B1 (en) | 2012-08-03 | 2021-03-31 | California Institute of Technology | Multiplexing and quantification in pcr with reduced hardware and requirements |
| WO2014037712A2 (en) * | 2012-09-04 | 2014-03-13 | Genome Research Limited | Hiv-1 detection |
| WO2015118491A1 (en) * | 2014-02-06 | 2015-08-13 | University Of The Witwatersrand, Johannesburg | Method for detecting hiv |
| DE112016003948T5 (de) | 2015-08-31 | 2018-05-09 | City Of Sapporo | Molekulare verfahren zum beurteilen einer urothelialen erkrankung |
| WO2017218777A1 (en) | 2016-06-17 | 2017-12-21 | California Institute Of Technology | Nucleic acid reactions and related methods and compositions |
| US12454720B2 (en) | 2018-04-17 | 2025-10-28 | ChromaCode, Inc. | Methods and systems for multiplex analysis |
| US12203129B2 (en) | 2018-07-03 | 2025-01-21 | ChromaCode, Inc. | Formulations and signal encoding and decoding methods for massively multiplexed biochemical assays |
| US20220119787A1 (en) * | 2019-02-20 | 2022-04-21 | Biomedrex Ab | Virus therapy |
| KR102191513B1 (ko) | 2020-02-13 | 2020-12-15 | 주식회사 에스씨엘헬스케어 | Hiv-1 약제 내성 분석을 위한 프라이머 세트, 이를 포함하는 키트, 및 이를 이용한 분석 방법 |
| CN112795699A (zh) * | 2021-02-09 | 2021-05-14 | 南方医科大学 | 一种rt-raa荧光法检测hiv-1病毒不同亚型通用引物、探针及检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| EP0215942B1 (en) | 1985-03-15 | 1995-07-12 | Antivirals Inc. | Polynucleotide assay reagent and method |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
| US6004826A (en) * | 1988-07-20 | 1999-12-21 | David Segev | Repair-mediated process for amplifying and detecting nucleic acid sequences |
| CA2003383A1 (en) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
| ES2066887T3 (es) * | 1989-02-03 | 1995-03-16 | Abbott Lab | Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1. |
| DE69034260D1 (de) * | 1989-06-02 | 2008-09-25 | Pasteur Institut | Nukleotid-Sequenzen von HIV-1, HIV-2 und SIV Retrovirusgenomen, ihre Verwendung zur Amplifizierung von diesen Retroviren und zur In Vitro Diagnostik von diesen Viren verursachten Infektionen |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| US5424414A (en) | 1991-12-17 | 1995-06-13 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids |
| US5464746A (en) | 1991-12-17 | 1995-11-07 | Abbott Laboratories | Haptens, tracers, immunogens and antibodies for carbazole and dibenzofuran derivatives |
| WO1993024656A1 (en) | 1992-05-29 | 1993-12-09 | Abbott Laboratories | Ligase chain reaction starting with rna sequences |
| US5925517A (en) * | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| CA2176348C (en) * | 1993-11-12 | 2004-11-02 | Sanjay Tyagi | Hybridization probes for nucleic acid detection, universal stems, methods and kits |
| US5733781A (en) * | 1994-07-19 | 1998-03-31 | Gen-Probe Incorporated | Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus |
| US5962665A (en) * | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
| US6001558A (en) * | 1997-06-25 | 1999-12-14 | Ortho Clinical Diagnostics, Inc. | Amplification and detection of HIV-1 and/or HIV 2 |
| US6391544B1 (en) * | 1998-05-15 | 2002-05-21 | Abbott Laboratories | Method for using unequal primer concentrations for generating nucleic acid amplification products |
| DE19850186A1 (de) * | 1998-10-30 | 2000-05-25 | Roche Diagnostics Gmbh | Neue Primer und Sonden zum Nachweis von HIV |
| US6300075B1 (en) * | 1999-02-03 | 2001-10-09 | Ortho-Clinical Diagnostics, Inc | Enhancement of the specificity of nucleic acid amplification by carrier nucleic acid |
| AU3219400A (en) * | 1999-02-03 | 2000-08-25 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and reagents for molecular detection of hiv-1 groups m, n and |
| ATE421999T1 (de) * | 1999-07-09 | 2009-02-15 | Gen Probe Inc | Nachweis von hiv-1 durch amplifizierung von nukleinsäuren |
| US6294338B1 (en) * | 1999-07-23 | 2001-09-25 | Gen-Probe Incorporated | Polynucleotide amplification method |
| US6936414B2 (en) * | 1999-12-22 | 2005-08-30 | Abbott Laboratories | Nucleic acid isolation method and kit |
-
2001
- 2001-09-04 US US09/945,943 patent/US6852491B2/en not_active Expired - Fee Related
-
2002
- 2002-07-12 WO PCT/US2002/022230 patent/WO2003020878A2/en not_active Ceased
- 2002-07-12 EP EP11154836A patent/EP2385144A1/en not_active Withdrawn
- 2002-07-12 CA CA2736621A patent/CA2736621A1/en not_active Abandoned
- 2002-07-12 JP JP2003525582A patent/JP4413610B2/ja not_active Expired - Fee Related
- 2002-07-12 EP EP02750006A patent/EP1430069A4/en not_active Withdrawn
- 2002-07-12 CA CA2459354A patent/CA2459354C/en not_active Expired - Fee Related
- 2002-07-12 EP EP11154847.5A patent/EP2390259B1/en not_active Expired - Lifetime
- 2002-07-12 ES ES11154847.5T patent/ES2458556T3/es not_active Expired - Lifetime
-
2009
- 2009-08-03 JP JP2009180578A patent/JP5205346B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-08 JP JP2012246079A patent/JP2013063072A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20030148280A1 (en) | 2003-08-07 |
| US6852491B2 (en) | 2005-02-08 |
| WO2003020878A2 (en) | 2003-03-13 |
| JP4413610B2 (ja) | 2010-02-10 |
| JP2009291202A (ja) | 2009-12-17 |
| EP2390259A2 (en) | 2011-11-30 |
| JP5205346B2 (ja) | 2013-06-05 |
| WO2003020878A3 (en) | 2004-01-29 |
| EP1430069A2 (en) | 2004-06-23 |
| CA2459354A1 (en) | 2003-03-13 |
| EP2390259A3 (en) | 2012-05-02 |
| ES2458556T3 (es) | 2014-05-06 |
| EP1430069A4 (en) | 2007-04-04 |
| EP2385144A1 (en) | 2011-11-09 |
| EP2390259B1 (en) | 2014-03-05 |
| JP2013063072A (ja) | 2013-04-11 |
| CA2459354C (en) | 2011-06-14 |
| JP2005507655A (ja) | 2005-03-24 |
| HK1164326A1 (en) | 2012-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2459354C (en) | Amplification and detection reagents for hiv-1 | |
| US9074262B2 (en) | Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1 | |
| US6232455B1 (en) | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 | |
| US20040072148A1 (en) | Simultaneous detection of HBV, HCV, and HIV in plasma samples using a multiplex capture assay | |
| Swanson et al. | Quantification of HIV-1 group M (subtypes A–G) and group O by the LCx HIV RNA quantitative assay | |
| US8575324B2 (en) | Methods and reagents for molecular detection of HIV-1 groups M, N and O | |
| HK1163754A (en) | Amplification and detection reagents for hiv-1 | |
| Ayele et al. | Surveillance technology for HIV-1 subtype C in Ethiopia: An env-based NASBA molecular beacon assay to discriminate between subcluster C and C′ | |
| HK1164326B (en) | Amplification and detection reagents for hiv-1 | |
| González-Villaseñor et al. | A solid phase plate assay for HIV-1 genotyping |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150714 |